All Rice Bran Derivatives Are Not Equal

The Role of Micronutrients and Bioavailability

When comparing rice bran derivatives and their 100-gram reports, it is essential to understand the role bioavailability plays in the nutritional potency of the product versus the simple aggregate (globular) nutritional comparison.

Unlike Nutra-Iso®, all other rice bran derivatives are created using a commercially available standard enzyme treatment (SET) process.  After more than seven years of R&D, Quintessence Nutraceuticals developed a transformational technology using an enhanced enzyme treatment (EET) process. This patented technology produces a product (Nutra-Iso®) that contains significantly higher levels of bioavailable protein, good fats, antioxidants and micronutrients resulting in a much more pharmacologically efficacious product.

Laboratory Analysis.  100-gram reports for EET and SET derived products may appear to be similar based on standard aggregate nutritional analyses. However, these standard reports are based on a globular macronutrient nutritional profile analysis of the individual ingredients (protein, fat, carbohydrate, etc.) and do not express the bioavailability of each nutritional component.  As shown in the table, the antioxidant embodiment of the EET product (Nutra-Iso®) is much higher and therein lies an important key to significantly improved bioavailability.

As further documented in an independent OA Laboratory analysis, the EET process yields significantly higher availability of fats (antioxidants and carbohydrates) and protein (peptide profile) as compared to the SET process. This next table shows that the percentage of protein in the product derived from the SET process is 0.83% versus 2.65% for the EET process. Herein lies the reason why the 100-gram report for the SET product is not equal to the 100-gram QNI report for Nutra-Iso® in terms of nutritional potency – bioavailability. The EET hydrolyzed protein is over three times that of the SET.

Selected Micronutrient Comparison* 

Nutrient SET Product Nutra-Iso® Difference
Tocopherols
10
ppm
21.1
211.0%
Tocotreinols
13
ppm
22.8
175.4%
Phytosterols
519
mg
940
181.1%
Oryzanols
230
mg
250
108.7%
*Aggregate macroanalysis-to-aggregate macroanalysis does not address bioavailability

Comparison of the Isolates Derived From the Standard Enzyme
Treatment (SET) Versus the Enhanced Enzyme Treatment (EET)

Begin Wt. (G)
Decant Wt. (G)
% Solids
Dry Basis Wt. (G)
% As-Is Fat
% As-Is Protein
SET Four Sample Average
180
103.75
7.14
7.39
0.93
0.83
EET Four Sample Average
180
113.00
11.41
12.89
2.50
2.65

EET Improvement

 Amount
%
0
0%
9.25
8.9%
4.27
59.8%
5.50
74.4%
1.56
167.6%
1.82
220.9%

Going back to the aggregate analysis for protein in the 100-gram reports, it is important to note that proteins in the aggregate are macromolecules (globular proteins) of long amino acid residues, and that’s how they are analyzed and reported in 100-gram reports. These protein macromolecules are only somewhat water soluble and must be further broken-down (hydrolyzed into short chains of peptides) to achieve the greater bioavailability and bioactive benefit within the human body (catalyzing metabolic functions, nutrient efficacy, etc.).

In commercial practice this is important because the hydrolyzed value of the EET derived product requires significantly less aggregate protein to achieve the same end benefit when incorporated into a nutritional supplement formulation. In effect, over three times the SET derived product would be required to achieve the same performance result as the EET derived product (Nutra-Iso®).

Clinical Study Results.  In a clinical trial conducted with lactating mothers and their breastfed infants, the bioavailability of Nutra-Iso® was clearly demonstrated by producing a meaningful change in the key metrics of newborn infants.  With lactating mothers’ normal diets supplemented solely by a daily regimen of Nutra-Iso®, this result was achieved through the increased quantity of breast milk produced by lactating mothers as well as what appears to be the increased “quality” of the breast milk received by the infants.  Without the exceptional bioavailability of Nutra-Iso®, the additional breast milk would not have been produced and the nutrients would not have had a bioactive benefit in the mother’s system to be passed on to the infants.  (See the full study results.)

Patentability.  One additional indicator of the significant difference between the SET derived products and the EET derived product (Nutra-Iso®) relates to patentability.  An important clinical study on rice bran derivatives was completed in 2002 by Dr. Qureshi1 based on products produced using the SET process.  Although many attempts were made to get a patent using the results of that comprehensive clinical trial, no one was able to achieve patent status for the SET process.  The problem was that the SET process did not achieve the performance levels required by the USPTO to rise above ‘prior art’ standards in nutritional potency (i.e., not ‘unique’ and ‘no surprising result’). In contrast, Quintessence’s EET process achieved the performance levels required to rise above the ‘prior art.’ As documented in the Patent Examiner’s approval report, the EET process was both ‘unique’ and ‘a surprising result.’ Simply put, QNI’s patented EET process achieved patent status because the process was scientifically documented as being measurably superior to the SET process.

The Bottom Line.  In terms of nutritional potency and pharmacological efficacy, 100 grams of SET derived product is not equivalent to 100 grams of EET derived product (Nutra-Iso®).

[1]Effects of stabilized rice bran, its soluble and fiber fractions on blood glucose and serum lipid parameters in humans with diabetes mellitus Types I and II – Qureshi, et.al – Journal of Nutritional Biochemistry 13 (2002), pages 175-187.